Biotech Values

[DewDiligence]

Re: BMY’s all-oral HCV trial

…it is also in nulls - which i have to think was the only way to get this study past the FDA

I agree on this specific point—for first-line subgroups other than null responders, the FDA would not have allowed BMY to run a 48-week all-oral arm that lacked an SoC bailout option.